Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): A randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance

  1. Molina, J.-M.
  2. Ait-Khaled, M.
  3. Rinaldi, R.
  4. Penco, G.
  5. Baril, J.-G.
  6. Cauda, R.
  7. Soriano, V.
  8. Pialoux, G.
  9. Wire, M.B.
  10. Lou, Y.
  11. Givens, N.
  12. Craig, C.
  13. Nichols, G.W.
  14. Barbosa, I.
  15. Yeo, J.
  16. Cooper, D.
  17. Clumeck, N.
  18. Trottier, S.
  19. Smith, G.
  20. Logue, K.
  21. Conway, B.
  22. Tsoukas, C.
  23. Partisiani, M.-L.
  24. Sereni, D.
  25. Lafeuillade, A.
  26. Bergmann, J.-F.
  27. Khuong-Josses, M.-A.
  28. Bouchaud, O.
  29. Plettenberg, A.
  30. Gargalianos-Kakolyris, P.
  31. Chrysos, G.
  32. Sighinolfi, L.
  33. Mazzotta, F.
  34. Filice, G.
  35. Caramello, P.
  36. Blanco, F.
  37. Domingo, P.
  38. Estrada, V.
  39. Pulido, F.
  40. Terrón, J.A.
  41. Górgolas, M.
  42. Coll, B.
  43. Portilla, J.
  44. Johnson, M.
  45. Huengsberg, M.
  46. Easterbrook, P.
  47. Winston, A.
  48. Erakutsi egile guztiak +
Aldizkaria:
Journal of Antimicrobial Chemotherapy

ISSN: 0305-7453,  1460-2091

Argitalpen urtea: 2009

Alea: 64

Zenbakia: 2

Orrialdeak: 398-410

Mota: Artikulua

DOI: 10.1093/JAC/DKP198 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus